Jemperli (dostarlimab) + Chemo
1L Endometrial Cancer
Key Facts
About GSK
GSK is a fully focused, global biopharma leader with a market cap exceeding $112B, formed in 2000 and sharpened by the 2022 demerger of its consumer health business. The company leverages deep expertise in vaccines, immunology, and genetics to build a robust pipeline across its four core therapeutic areas. Its strategy is centered on disciplined R&D investment in high-value modalities, including long-acting therapies and next-generation oncology agents, to drive sustainable growth and significant public health impact.
View full company profileTherapeutic Areas
Other 1L Endometrial Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Jemperli (dostarlimab) | GSK plc | Phase III |